Shanghai HeartCare H1 FY26 profit climbs 18.5% to RMB 60.37 million; revenue rises 56.9% to RMB 291.03 million

• Shanghai HeartCare posted revenue of RMB 291.03 million, up 56.9% year over year; profit attributable to owners rose 18.5% to RMB 60.37 million.
• Basic earnings per share increased to RMB 1.61; gross margin widened 3.3 percentage points to 71.5%.
• Growth was attributed to wider clinical recognition and rising end-market demand, supporting sustained revenue and profit expansion.
• Hemorrhagic stroke became the fastest-growing segment; Vascular Reconstruction Device entered 270+ new hospitals, with sales volume up over 80%.
• Proposed A-share listing plan advanced, with a board-approved application to issue 7,025,592 A Shares on Shanghai’s STAR Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308207), on August 31, 2026, and is solely responsible for the information contained therein.